Showing 321 - 340 results of 16,164 for search '(( significant ((mean decrease) OR (we decrease)) ) OR ( significantly increased decrease ))', query time: 0.61s Refine Results
  1. 321

    Fig 1 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  2. 322

    Fig 5 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  3. 323
  4. 324
  5. 325
  6. 326

    Fig 10 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  7. 327
  8. 328

    Fig 4 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  9. 329

    Fig 9 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  10. 330

    Fig 6 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  11. 331

    Fig 7 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  12. 332

    Fig 8 - by Farshid Maleki (20521649)

    Published 2025
    Subjects:
  13. 333

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  14. 334

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  15. 335

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  16. 336
  17. 337
  18. 338

    Means scores of CAM and CAM-MYCS. by Senay Yildirim-Kahriman (22693464)

    Published 2025
    “…A moderate negative correlation was observed between CAM and CAM-MYCS scores (r = −0.511; p < 0.001), indicating that increased awareness of real causes is associated with decreased belief in myths. …”
  19. 339

    Data. by Aroon La-up (14095691)

    Published 2025
    “…This study found a statistically significant decrease in BMD in the group with the lowest U-Cd levels (<2.0 μg/g creatinine, p = 0.001) and in the overall sample (from 0.392 ± 0.079 μg/g creatinine in 2019 to 0.384 ± 0.094 μg/g creatinine in 2022, p = 0.004). …”
  20. 340